Hodgkin’s Lymphoma in HIV-Infected Patients

AV Pivnik1, AM Vukovich2, NV Kremneva1, MG Dubnitskaya1, AV Tsakhilova1

1 AS Loginov Moscow Clinical Scientific Center, 86 Entuziastov sh., Moscow, Russian Federation, 111123

2 IM Sechenov First Moscow State Medical University, 8 bld. 2 Trubetskaya str., Moscow, Russian Federation, 119991

For correspondence: Prof. Aleksandr Vasilevich Pivnik, MD, PhD, 86 Entuziastov sh., Moscow, Russian Federation, 111123; Tel.: +7(906)065-99-32; e-mail: pivnikav@gmail.com

For citation: Pivnik AV, Vukovich AM, Kremneva NV, et al. Hodgkin’s Lymphoma in HIV-Infected Patients. Clinical oncohematology. 2021;14(1):63–8. (In Russ).

DOI: 10.21320/2500-2139-2021-14-1-63-68


Aim. To assess clinical and laboratory characteristics of the unique category of HIV-positive patients with hepatitis C or B co-infection combined with Hodgkin’s lymphoma (HL).

Materials & Methods. The paper provides data on 85 HIV-positive patients with HL followed-up at the Department of Hematology and Secondary Immunodeficiencies of the AS Loginov Moscow Clinical Scientific Center from 2002 to 2019 (data on 2008–2010 are not available). The distribution of patients by sex was approximately equal, median age was 35 years (range 20–74 years).

Results. Histological HL variant is predominantly mixed-cell with many positive tests for Epstein-Barr virus. More than 80 % of patients with concomitant HIV infection were admitted to the AS Loginov Center with HL stage III/IV. Most of them received highly active anti-retroviral therapy (HAART) before HL diagnosis. The distinguishing feature of HIV-positive patients with HL appeared to be high (as compared to HIV patients with other lymphoma variants) CD4+ lymphocyte count. This phenomenon is considered within the framework of immune reconstitution inflammatory syndrome (IRIS). A clue to this phenomenon may lay the foundation in addressing the issue of lymphoma genesis and development. Viral load was moderate and undetectable. Hepatitis C and/or B co-infection was identified in 75 % of patients. Antiviral therapy for concomitant hepatitis C was administered concurrent with HAART. All patients received АBVD, BEACOPP-14, BEACOPP-escalated, DHAP, ESHAP antitumor regimens. Radiotherapy was used if necessary. In hepatitis C HAART and direct-acting drugs were administered concurrent with chemotherapy. No severe adverse reactions were observed. Even before starting antitumor treatment of HL patients with concomitant HIV and/or hepatitis viral infections, mortality was 8 %. But in the group of patients with the same co-infections who received HL chemotherapy, mortality was 10 %. The cause of death was HL stage IVB with viral liver cirrhosis, agranulocytosis, and sepsis.

Conclusion. Diseases considered incurable in the past, such as HL and hepatitis C, can be healed today. Compromised immunity of HIV-positive patients can be successfully stabilized with HAART.

Keywords: Hodgkin’s lymphoma, HIV infection, immune reconstitution inflammatory syndrome (IRIS).

Received: April 4, 2020

Accepted: November 9, 2020

Read in PDF

Статистика Plumx английский


  1. Geller SA. Comments on the anniversary of the description of Hodgkin’s disease. J Natl Med Assoc. 1984;76(8):815–817.
  2. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswold’s meeting. J Clin Oncol. 1989;7(11):1630–6. doi: 10.1200/jco.1989.7.11.1630.
  3. Демина Е.А., Тумян Г.С., Чекан А.А. и др. Редкое заболевание — нодулярная лимфома Ходжкина с лимфоидным преобладанием: обзор литературы и собственные наблюдения. Клиническая онкогематология. 2014;7(4):522–32.
    [Demina EA, Tumyan GS, Chekan AA, et al. Rare Disease — Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma: Literature Review and Own Data. Klinicheskaya onkogematologiya. 2014;7(4):522–32. (In Russ)]
  4. Гурцевич В.Э. Вирус Эпштейна—Барр и классическая лимфома Ходжкина. Клиническая онкогематология. 2016;9(2):101–14. doi: 10.21320/2500-2139-2016-9-2-101-114.
    [Gurtsevitch VE. Epstein-Barr Virus and Classical Hodgkin’s Lymphoma. Clinical oncohematology. 2016;9(2):101–14. doi: 10.21320/2500-2139-2016-9-2-101-114. (In Russ)]
  5. Демина Е.А. Брентуксимаб ведотин: новые возможности лечения рецидивов и рефрактерных форм лимфомы Ходжкина. Клиническая онкогематология. 2016;9(4):398–405. doi: 10.21320/2500-2139-2016-9-4-398-405.
    [Demina EA. Brentuximab Vedotin: New Possibilities for Treatment of Relapses and Refractory Hodgkin’s Lymphomas. Clinical oncohematology. 2016;9(4):398–405. doi: 10.21320/2500-2139-2016-9-4-398-405. (In Russ)]
  6. Демина Е.А. Блокада PD-1-пути ниволумабом — новая возможность иммунотерапии классической лимфомы Ходжкина. Клиническая онкогематология. 2018;11(3):213–9. doi: 10.21320/2500-2139-2018-11-3-213-219.
    [Demina EA. PD-1 Blockade with Nivolumab as a New Immunotherapy for Classical Hodgkin’s Lymphoma. Clinical oncohematology. 2018;11(3):213–9. doi: 10.21320/2500-2139-2018-11-3-213-219. (In Russ)]
  7. Насибов О.М. Фиброз легких, кардиопатии и вторичных опухоли у лиц в длительной ремиссии лимфогранулематоза: Дис.… канд. мед. наук. М., 2000. 114 с.
    [Nasibov OM. Fibroz legkikh, kardiopatii i vtorichnykh opukholi u lits v dlitelnoi remissii limfogranulematoza. (Pulmonary fibrosis, cardiopathies and secondary tumors during long lymphogranulomatosis remission.) [dissertation] Moscow; 2000. 114 p. (In Russ)]
  8. Куприна И.В. Состояние щитовидной железы и особенности липидного обмена у больных лимфогранулематозом молодого и среднего возраста после комбинированной химиолучевой терапии: Дис.… канд. мед. наук. М., 2008. 122 с.
    [Kuprina IV. Sostoyanie shchitovidnoi zhelezy i osobennosti lipidnogo obmena u bolnykh limfogranulematozom molodogo i srednego vozrasta posle kombinirovannoi khimioluchevoi terapii. (Thyroid status and lipid metabolism characteristics in young and middle-aged lymphogranulomatosis patients after combined chemoradiation therapy.) [dissertation] Moscow; 2008. 122 p. (In Russ)]
  9. Philippova MM, Khachin DP, Sazonova OV, et al. Fragments of functional proteins in a primary culture of human erythrocytes. Russ J Bioorg Chem. 2008;34(2):145–55. doi: 10.1134/S1068162008020027.
  10. Pivnik AV, Rasstrigin NA, Philippova MM, et al. Alteration of Intraerythrocyte Proteolytic Degradation of Hemoglobin During Hodgkin’s Disease. Leuk Lymphoma. 1996;22(3–4):345–9. doi: 10.3109/10428199609051767.
  11. Непомнящая Н.И. Психологический аспект онкологических заболеваний. Психологический журнал. 1998;4:132–45.
    [Nepomnyashchaya NI. The psychological aspect of oncological diseases. Psikhologicheskii zhurnal. 1998;4:132–45. (In Russ)]
  12. Расстригин Н.А. Альтернирующая полихимиотерапия лимфогранулематоза: Дис. … канд. мед. наук. М., 1999. 124 с.
    [Rasstrigin NA. Alterniruyushchaya polikhimioterapiya limfogranulematoza. (Alternating polychemotherapy of lymphogranulomatosis.) [dissertation] Moscow; 1999. 124 p. (In Russ)]
  13. Асланиди И.П., Мухортова О.В., Катунина Т.А. и др. Современные аспекты применения позитронно-эмиссионной томографии при лимфомах. Клиническая онкогематология. 2015;8(1):13–25. doi: 10.21320/2500-2139-2015-8-1-13-25.
    [Aslanidi IP, Mukhortova OV, Katunina TA, et al. Positron Emission Tomography in Modern Management of Lymphomas. Clinical oncohematology. 2015;8(1):13–25. doi: 10.21320/2500-2139-2015-8-1-13-25. (In Russ)]
  14. Khamaganova E, Aleschenko S, Murashova L, Zaretskaya Y. Immunogenetic factors of predisposition to blood malignancies in Russian population. Russ J Immunol. 2001;6(3):265–70.
  15. Swerdlow SH, Campo E, Pileri SA. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. 2016;127(20):2375–90. doi: 10.1182/blood-2016-01-643569.
  16. The Nobel Prize. Available from: https://www.nobelprize.org/prizes/medicine/2008/press-release/ (accessed 27.10.2020).
  17. ЮНЭЙДС. COVID-19 и ВИЧ [электронный документ]. Доступно по: https://www.unaids.org/ru. Ссылка активна на 10.2020.
    [UNAIDS. COVID-19 and HIV. [Internet] Available from: https://www.unaids.org/ru. (accessed 27.10.2020) (In Russ)]
  18. ВИЧ-инфекция и СПИД: национальное руководство. Под ред. В.В. Покровского. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2020. 696 с. doi: 10.33029/9704-5421-3-2020-VIC-1-696.
    [Pokrovsky VV, ed. VICh-infektsiya i SPID: natsionalnoe rukovodstvo. (HIV infection and AIDS: Federal Guidelines.) 2nd edition, revised and enlarged. Moscow: GEOTAR-Media Publ.; 2020. 696 p. doi: 10.33029/9704-5421-3-2020-VIC-1-696. (In Russ)]
  19. Barre-Sinoussi F, Ross AL, Delfraissy JF. Past, present and future: 30 years of HIV research. Nat Rev Micr 2013;11(12):877–83. doi: 10.1038/nrmicro3132.
  20. Lu DY, Wu HY, Yarla NS, et al. HAART in HIV/AIDS Treatments: Future Trends. Infect Disord Drug Targ. 2018;18(1):15–22. doi: 10.2174/1871526517666170505122800.
  21. Brown I am the Berlin patient: a personal reflection. AIDS Res Hum Retrovir. 2015;31(1):2–3. doi: 10.1089/AID.2014.0224.
  22. Gallagher Berlin patient: First person cured of HIV, Timothy Ray Brown, dies. Available from: https://www.bbc.com/news/health-54355673. (accessed 27.10.2020).
  23. Пивник А.В., Туманова М.В., Чистякова А.В. и др. Анализ стационарной помощи инфицированным ВИЧ больным злокачественными лимфомами и гепатитами за 5 лет (2011–2015 гг.) в МКНЦ им. А.С. Логинова ДЗМ. Терапевтический архив. 2017;89(7):105–11. doi: 10.17116/terarkh2017897105-111.
    [Pivnik AV, Tumanova MV, Chistyakova AV, et al. Analysis of inpatient care for HIV-positive patients with malignant lymphomas and hepatitis over 5 years (2011–2015) at the A.S. Loginov Moscow Clinical Research Center, Moscow Healthcare Department. Terapevticheskii arkhiv. 2017;89(7):105–11. doi: 10.17116/terarkh2017897105-111. (In Russ)]
  24. Lucas S, Nelson AM. HIV and the spectrum of human disease. J Pathol. 2015;235(2):229–41. doi: 1002/path.4449.
  25. Hosoda T, Uehara Y, Kasuga T, et al. An HIV-infected patient with acute retinal necrosis as immune reconstitution inflammatory syndrome due to varicella-zoster virus. AIDS. 2020;34(5):795–6. doi: 10.1097/QAD.0000000000002477.
  26. Namale PE, Abdullahi LH, Fine S. Paradoxical TB-IRIS in HIV-infected adults: a systematic review and meta-analysis. Fut Microbiol. 2015;10(6):1077–99. doi: 10.2217/fmb.15.9.
  27. Пивник А.В., Туманова М.В., Серегин Н.В. и др. Лимфомы у ВИЧ-инфицированных больных: обзор литературы. Клиническая онкогематология. 2014;7(3):264–77.
    [Pivnik AV, Tumanova MV, Seregin NV, et al. Lymphomas in HIV­Infected Patients: Literature Review. Klinicheskaya onkogematologiya. 2014;7(3):264–77. (In Russ)]
  28. Лейгтон Р.А., ПивникА.В., Сергеева Е.П. и др. Плазмоклеточные опухоли у ВИЧ-инфицированных пациентов (обзор литературы и собственные наблюдения). Клиническая онкогематология. 2017;10(4):464–70. doi: 10.21320/2500-2139-2017-10-4-464-470.
    [Leigton RA, Pivnik AV, Sergeeva EP, et al. Plasma cell neoplasms in HIV-Infected Patients: A Literature Review and Case Series. Clinical oncohematology. 2017;10(4):464–70. doi: 10.21320/2500-2139-2017-10-4-464-470. (In Russ)]